Yeah...a question that bothers me as well. Confirmatory P3 would pay or at least cover the treatment costs for the participants...and probably at the end all could get on A 2-73...but those on placebo deteriorate during that portion of the trial. This is one of the reasons I think a P4 could be in play. The trick would be how to construct the control...is there enough data already available including biomarkers?
Market Data 
Markets 
AI
